FIXX News and Press, Homology Medicines Inc. From 04/06/21

Gainers: [[AKBA]] +12.1%. [[SYBX]] +7.1%. [[ARDX]] +5.2%. [[ODT]] +4.9%. [[BYND]] +4.2%.Losers: [[FGEN]] -29.2%. [[FIXX]] -10.2%. [[MAXN]] -6.8%. [[IONS]] -5.8%. [[OM]] -5.4%. For further details see: AKBA, SYBX, FGEN and FIXX among after-hours movers

Homology Medicines (FIXX) announces that the company intends to offer and sell $50M of shares in an underwritten public offering.Expects to grant the underwriter a 30-day option to purchase up to an additional $7.5M shares.Intends to use the net proceeds from the offering, in addition to...

- Phase 2 PKU Gene Therapy Trial Recruiting Patients With Initial Data Expected by Year End - - On Track to Initiate Phase 1/2 Trials With In Vivo Gene Editing Candidate for PKU and Gene Therapy Candidate for Hunter Syndrome This Year - - Plans to Name a New De...

- Company plans to continue advancing ophthalmic program toward a development candidate for lead indication - BEDFORD, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today it has re...

BEDFORD, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today presentations at the following virtual conferences: Cowen 41 st Annual Health Care Conference Panel discussion: March 1 at 1...

- IND-Enabling Studies Demonstrated Potential of a Single I.V. Administration of HMI-203 to Address Peripheral and CNS Components of Disease - - Data at WORLD Symposium ™ Support Plans to Initiate a HMI-203 Phase 1/2 Clinical Trial This Year - BEDF...

Gainers: [[VIVO]] +6%. [[ABUS]] +4.6%. [[AY]] +4.2%. [[EBON]] +3.5%. [[TSE]] +3.4%.Losers: [[ACLS]] -14%. [[DOGZ]] -8.5%. [[HX]] -7.8%. [[FIXX]] -5.9%. [[JRJC]] -2.1%. For further details see: AY, ABUS, ACLS and FIXX among after-hours movers

Homology Medicines ([[FIXX]] +4.3%) has outlined plans to initiate two additional Phase 1/2 dose-escalation trials in 2021 with its gene therapy candidate for Hunter syndrome and gene editing candidate, which is for Phenylketonuria ((PKU)).Additionally, the company plans to nam...

- Clinical Data from pheNIX Gene Therapy Phase 2 Dose Expansion Trial Expected by End of Year; Trial Currently Recruiting Patients - - Company Plans to Nominate Additional Development Candidate in New Therapeutic Area - - Management Highlights Anticipated 2021 Milestones...

Homology Medicines is a US-based genetic medicines biotech company aiming to treat rare genetic diseases with an unmet medical need. Homology Medicines has a pipeline of 1 Phase 1/2 therapeutic (HMI-102), 3-IND-enabling phase therapeutics, and 3 in the early research phase on top of t...